Skip to content

Study · Observational study · n = 10,625 · 2026

8 results

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).

Wilson L, Zhao Z, Divino V, Bassan M, Hartaigh BÓ, Stensen S, Ozer K

Diabetes, obesity & metabolism5 Jan 2026Cited by 12 (Europe PMC)

PMID41491349 (opens in a new tab)PMCIDPMC12890754 (opens in a new tab)DOI10.1111/dom.70436 (opens in a new tab)PepBankPUB-41491349
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with overweight or obesity and atherosclerotic cardiovascular disease without diabetes, semaglutide was associated with a 29% lower risk of rMACE-3 than tirzepatide (HR 0.71).

    In plain wordsIn adults with overweight or obesity and heart or vessel disease, semaglutide was linked to fewer major heart events than tirzepatide.

    Peptide
    Semaglutide
    Outcome
    DecreaserMACE-3 risk
    Study

    n = 10,625

    Comparator
    Tirzepatide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.71 ratio
    semaglutide vs tirzepatide, rMACE-3

    Source sentences

    Summary
    Semaglutide was associated with statistically significant 29% (hazard ratio [HR] 0.71; p = 0.046) and 22% (HR 0.78; p = 0.040) reductions in the risk of rMACE-3
    2 context sentences
    Summary · context
    This retrospective, observational cohort study used Komodo Research Data and included patients ≥45 years of age with overweight/obesity and ≥1 claim for myocardial infarction (MI), ischemic stroke, or peripheral artery disease first treated with semaglutide or tirzepatide between 13/5/2022-31/1/2025.
    Summary · context
    Propensity score matching was used to balance key baseline characteristics between cohorts.
  2. 02HumanObservational studyEfficacy outcome

    In adults with overweight or obesity and atherosclerotic cardiovascular disease without diabetes, semaglutide was associated with a 22% lower risk of rMACE-5 than tirzepatide (HR 0.78).

    In plain wordsIn adults with overweight or obesity and heart or vessel disease, semaglutide was linked to fewer major heart events than tirzepatide.

    Peptide
    Semaglutide
    Outcome
    DecreaserMACE-5 risk
    Study

    n = 10,625

    Comparator
    Tirzepatide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.78 ratio
    semaglutide vs tirzepatide, rMACE-5

    Source sentences

    Summary
    Semaglutide was associated with statistically significant 29% (hazard ratio [HR] 0.71; p = 0.046) and 22% (HR 0.78; p = 0.040) reductions in the risk of rMACE-3 and rMACE-5, respectively, compared with tirzepatide.
    2 context sentences
    Summary · context
    This retrospective, observational cohort study used Komodo Research Data and included patients ≥45 years of age with overweight/obesity and ≥1 claim for myocardial infarction (MI), ischemic stroke, or peripheral artery disease first treated with semaglutide or tirzepatide between 13/5/2022-31/1/2025.
    Summary · context
    Propensity score matching was used to balance key baseline characteristics between cohorts.
  3. 03HumanObservational studyEfficacy outcome

    In adults with overweight or obesity and atherosclerotic cardiovascular disease without diabetes, tirzepatide was associated with a higher risk of rMACE-3 than semaglutide.

    In plain wordsIn adults with overweight or obesity and heart or vessel disease, tirzepatide was linked to more major heart events than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaserMACE-3 risk
    Study

    n = 10,625

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide was associated with statistically significant 29% (hazard ratio [HR] 0.71; p = 0.046) and 22% (HR 0.78; p = 0.040) reductions in the risk of rMACE-3
    2 context sentences
    Summary · context
    This retrospective, observational cohort study used Komodo Research Data and included patients ≥45 years of age with overweight/obesity and ≥1 claim for myocardial infarction (MI), ischemic stroke, or peripheral artery disease first treated with semaglutide or tirzepatide between 13/5/2022-31/1/2025.
    Summary · context
    Propensity score matching was used to balance key baseline characteristics between cohorts.
  4. 04HumanObservational studyEfficacy outcome

    In adults with overweight or obesity and atherosclerotic cardiovascular disease without diabetes, tirzepatide was associated with a higher risk of rMACE-5 than semaglutide.

    In plain wordsIn adults with overweight or obesity and heart or vessel disease, tirzepatide was linked to more major heart events than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaserMACE-5 risk
    Study

    n = 10,625

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide was associated with statistically significant 29% (hazard ratio [HR] 0.71; p = 0.046) and 22% (HR 0.78; p = 0.040) reductions in the risk of rMACE-3 and rMACE-5, respectively, compared with tirzepatide.
    2 context sentences
    Summary · context
    This retrospective, observational cohort study used Komodo Research Data and included patients ≥45 years of age with overweight/obesity and ≥1 claim for myocardial infarction (MI), ischemic stroke, or peripheral artery disease first treated with semaglutide or tirzepatide between 13/5/2022-31/1/2025.
    Summary · context
    Propensity score matching was used to balance key baseline characteristics between cohorts.
  5. 05HumanObservational studyEfficacy outcome

    In the per-protocol analysis, semaglutide remained associated with a lower risk of rMACE-3 than tirzepatide (HR 0.43).

    In plain wordsWhen patients who stopped treatment were left out, semaglutide was still linked to fewer major heart events than tirzepatide.

    Peptide
    Semaglutide
    Outcome
    DecreaserMACE-3 risk, per-protocol analysis
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.43 ratio
    semaglutide vs tirzepatide, rMACE-3, per-protocol

    Source sentences

    Summary
    In the per-protocol analysis, semaglutide continued to be associated with a significantly lower risk of rMACE-3 (HR 0.43; p = 0.005) and rMACE-5 (HR 0.57; p = 0.003) compared with tirzepatide.
    2 context sentences
    Summary · context
    This retrospective, observational cohort study used Komodo Research Data and included patients ≥45 years of age with overweight/obesity and ≥1 claim for myocardial infarction (MI), ischemic stroke, or peripheral artery disease first treated with semaglutide or tirzepatide between 13/5/2022-31/1/2025.
    Summary · context
    Propensity score matching was used to balance key baseline characteristics between cohorts.
  6. 06HumanObservational studyEfficacy outcome

    In the per-protocol analysis, semaglutide remained associated with a lower risk of rMACE-5 than tirzepatide (HR 0.57).

    In plain wordsWhen patients who stopped treatment were left out, semaglutide was still linked to fewer major heart events than tirzepatide.

    Peptide
    Semaglutide
    Outcome
    DecreaserMACE-5 risk, per-protocol analysis
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.57 ratio
    semaglutide vs tirzepatide, rMACE-5, per-protocol

    Source sentences

    Summary
    In the per-protocol analysis, semaglutide continued to be associated with a significantly lower risk of rMACE-3 (HR 0.43; p = 0.005) and rMACE-5 (HR 0.57; p = 0.003) compared with tirzepatide.
    2 context sentences
    Summary · context
    This retrospective, observational cohort study used Komodo Research Data and included patients ≥45 years of age with overweight/obesity and ≥1 claim for myocardial infarction (MI), ischemic stroke, or peripheral artery disease first treated with semaglutide or tirzepatide between 13/5/2022-31/1/2025.
    Summary · context
    Propensity score matching was used to balance key baseline characteristics between cohorts.
  7. 07HumanObservational studyEfficacy outcome

    In the per-protocol analysis, tirzepatide remained associated with a higher risk of rMACE-3 than semaglutide.

    In plain wordsWhen patients who stopped treatment were left out, tirzepatide was still linked to more major heart events than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaserMACE-3 risk, per-protocol analysis
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the per-protocol analysis, semaglutide continued to be associated with a significantly lower risk of rMACE-3 (HR 0.43; p = 0.005) and rMACE-5 (HR 0.57; p = 0.003) compared with tirzepatide.
    2 context sentences
    Summary · context
    This retrospective, observational cohort study used Komodo Research Data and included patients ≥45 years of age with overweight/obesity and ≥1 claim for myocardial infarction (MI), ischemic stroke, or peripheral artery disease first treated with semaglutide or tirzepatide between 13/5/2022-31/1/2025.
    Summary · context
    Propensity score matching was used to balance key baseline characteristics between cohorts.
  8. 08HumanObservational studyEfficacy outcome

    In the per-protocol analysis, tirzepatide remained associated with a higher risk of rMACE-5 than semaglutide.

    In plain wordsWhen patients who stopped treatment were left out, tirzepatide was still linked to more major heart events than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaserMACE-5 risk, per-protocol analysis
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the per-protocol analysis, semaglutide continued to be associated with a significantly lower risk of rMACE-3 (HR 0.43; p = 0.005) and rMACE-5 (HR 0.57; p = 0.003) compared with tirzepatide.
    2 context sentences
    Summary · context
    This retrospective, observational cohort study used Komodo Research Data and included patients ≥45 years of age with overweight/obesity and ≥1 claim for myocardial infarction (MI), ischemic stroke, or peripheral artery disease first treated with semaglutide or tirzepatide between 13/5/2022-31/1/2025.
    Summary · context
    Propensity score matching was used to balance key baseline characteristics between cohorts.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.